Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + pyrotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of carboplatin, a platinum-based chemotherapy agent, and pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. This combination targets HER2-positive breast cancer by combining the DNA-damaging effects of carboplatin with the HER1, HER2, and HER4 inhibition provided by pyrotinib. It has shown significant efficacy in clinical trials, particularly in the neoadjuvant setting for early or locally advanced HER2-positive breast cancer and in patients with trastuzumab resistance.
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on carboplatin + pyrotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + pyrotinib.